NCT00081731View on ClinicalTrials.gov

Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions

PHASE3CompletedINTERVENTIONAL
Enrollment

947

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
AtherosclerosisCardiovascular DiseasesHypertension, RenovascularRenal Artery Obstruction
Interventions
DRUG

Atacand/HCT, Caduet

Atacand/HCT and caduet or optimal medical therapy for hypertension

PROCEDURE

GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)

Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device

Trial Locations (1)

43614

University of Toledo, Toledo

Sponsors
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Baim Institute for Clinical Research

OTHER